Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: A potential therapy for primary hyperoxaluria

Kidney International

Volumn 67, Issue 1, 2005, Pages 53-60

  Chetyrkin, Sergei V ^b   Kim, Daniel ^b   Belmont, John M ^b   Scheinman, Jon I ^b   Hudson, Billy G ^b   Voziyan, Paul A ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

Kidney stone disease; Primary hyperoxaluria; Pyridoxamine

Indexed keywords

CALCIUM; CALCIUM OXALATE; CARBONYL DERIVATIVE; CREATININE; ETHYLENE GLYCOL; GLYCOLIC ACID; GLYOXYLIC ACID; OXALIC ACID; PYRIDOXAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIFICATION; CALCIUM URINE LEVEL; CONTROLLED STUDY; CREATININE URINE LEVEL; DIALYSIS; DRUG EFFECT; DRUG MECHANISM; GENETIC DISORDER; HYPEROXALURIA; IN VITRO STUDY; KIDNEY FAILURE; KIDNEY MEDULLA; KIDNEY PAPILLA; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; NEPHROLITHIASIS; NONHUMAN; PRIORITY JOURNAL; RARE DISEASE; RAT; URINALYSIS;

EID: 10944220190     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00054.x     Document Type: Article

References (42)

1. DANPURE CJ, LUMB MJ, BIRDSEY GM, ZHANG X: Alanine:glyoxylate aminotransferase peroxisome-to-mitochondrion mistargeting in human hereditary kidney stone disease. Biochim Biophys Acta 1647:70-75, 2003
2. SABORIO P, SCHEINMAN JI: Transplantation for primary hyperoxaluria in the United States. Kidney Int 56:1094-1100, 1999
3. MARANGELLA M: Transplantation strategies in type 1 primary hyperoxaluria: The issue of pyridoxine responsiveness. Nephrol Dial Transplant 14:301-303, 1999
4. MISTRY J, DANPURE CJ, CHALMERS RA: Hepatic D-glycerate dehydrogenase and glyoxylate reductase deficiency in primary hyperoxaluria type 2. Biochem Soc Trans 16:626-627, 1988
5. KEMPER MJ, CONRAD S, MULLER-WIEFEL DE: Primaryhyperoxaluria type 2. Eur J Pediatr 156:509-512, 1997
6. MONK RD, BUSHINSKY DA: Nephrolithiasis and nephrocalcinosis, in Comprehensive Clinical Nephrology, edited by Johnson JJ, Feehally J, London, Harcourt Publishers Limited, 2000, pp 60.1-60.12
7. MENON M, KOUL H: Clinical review 32: Calcium oxalate nephrolithiasis. J Clin Endocrin Metab 74:703-707, 1992
8. URIBARRI J, OH MS, CARROLL HJ: The first kidney stone. Ann Int Med 111:1006-1009, 1998
9. SUN BY, LEE YH, JIAAN BP, et al: Recurrence rate and risk factors for urinary calculi after extracorporeal shock wave lithotripsy. J Urol 156:903-905, 1996
10. HOLMES RP, GOODMAN HO, ASSIMOS DG: Dietary oxalate and its intestinal absorption. Scanning Microsc 9:1109-1118, 1995
11. 14C1]glyoxylate in the hepatectomized rat. Biochim Biophys Acta 757:8-14, 1983
12. BOOTH AA, KHALIFAH RG, TODD P, HUDSON BG: In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs): Novel inhibition of post-Amadori glycation pathways. J Biol Chem 272:5430-5437, 1997
13. VOZIYAN PA, KHALIFAH RG, THIBAUDEAU C, et al: Modification of proteins in vitro by physiological levels of glucose: Pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-products through binding of redox metal ions. J Biol Chem 278:46616-46624, 2003
14. VOZIYAN PA, METZ TO, BAYNES JW, HUDSON BG: A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J Biol Chem 277:3397-3403, 2002
15. NAGARAI RH, SARKAR P, MALLY A, et al: Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: Characterization of a major product from the reaction of pyridoxamine and methylglyoxal. Arch Biochem Biophys 402:110-119, 2002
16. METZ TO, ALDERSON NL, CHACHICH ME, et al: Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: Evidence on the role of lipids in chemical modification of protein and development of diabetic complications. J Biol Chem 278:42012-42019, 2003
17. KHAN SR: Animal models of kidney stone formation: An analysis. World J Urol 15:236-243, 1997
18. LYON ES, BORDEN TA, VERMEULEN CW: Experimental oxalate lithiasis produced with ethylene glycol. Invest Urol 4:143-151, 1996
19. LAKER MF, HOFMANN AF, MEEUSE BJ: Spectrophotometric determination of urinary oxalate with oxalate oxidase prepared from moss. Clin Chem 26:827-830, 1980
20. PETRARULO M, PELLEGRINO S, BIANCO O, et al: Derivatization and high-performance liquid Chromatographic determination of urinary glycolic acid. J Chromatogr 465:87-93, 1989
21. FIELDS R, DIXON HB: Micro method for determination of reactive carbonyl groups in proteins and peptides, using 2,4-dinitrophenylhydrazine. Biochem J 121:587-589, 1971
22. DEGENHARDT TP, ALDERSON NL, ARRINGTON DD, et al: Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 61:939-950, 2002
23. STITT A, GARDINER TA, ALDERSON NL, et al: The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51:2826-2832, 2002
24. DANPURE C: Primary hyperoxaluria, in The Metabolic and Molecular Bases of Inherited Disease, edited by Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Volgestein B, New York, McGraw-Hill, 2001, pp 3323-3367
25. SPADARO AC, DRAGHETTA W, DEL LAMA S, GREENE LJ: A convenient manual trinitrobenzenesulfonic acid method for monitoring amino acids and peptides in chromatographic column effluents. Anal Biochem 96:317-321, 1979
26. SOLOMONS CC, GOODMAN S., RILEY CM: Calcium carbimide in the treatment of primary hyperoxaluria. N Engl J Med 276:207-210, 1967
27. RODNEY CS, RANDALL WC, STREETER KB, et al: Inhibitors of glycolic acid oxidase. 4-Substituted 3-hydroxy-1H-pyrrole-2,5-dione derivatives. J Med Chem 26:700-714, 1983
28. BRENT J, MCMARTIN K, PHILLIPS S, et al: Fomepizole for the treatment of ethylene glycol poisoning. N Engl J Med 340:832-838, 1999
29. TULLY DB, ALLGOOD VE, CIDLOWSKI JA: Modulation of steroid receptor-mediated gene expression by vitamin 65. FASEB J 8:343-349, 1994
30. WANDERS RJ, VAN ROERMUND CW, JURRIAANS S, et al: Diversity in residual alanine glyoxylate aminotransferase activity in hyperoxaluria type I: Correlation with pyridoxine responsiveness. J Inherit Metab Dis 11 (Suppl 2):208-211, 1998
31. SCHEINMAN JI: Primary hyperoxaluria: therapeutic strategies for the 90's. Kidney Int 40:389-399, 1991
32. CURHAN GC, WILLETT WC, SPEIZER FE, STAMPFER MJ: Intake of vitamins B6 and C and the risk of kidney stones in women. J Am Soc Nephrol 10:840-845, 1999
33. CURHAN GC, WILLETT WC, RIMM EB, STAMPFER MJ: A prospective study of the intake of vitamins C and B6, and the risk of kidney stones in men. J Urol 155:1847-1851, 1996
34. EDWARDS P, NEMAT S, ROSE GA: Effects of oral pyridoxine upon plasma and 24-hour urinary oxalate levels in normal subjects and stone formers with idiopathic hypercalciuria. Urol Res 18:393-396, 1990
35. BAKER PW, ROFE AM, BAIS R: The effect of (L)-cysteine and (L)-2-oxothiazolidine-4-carboxylic acid (OTZ) on urinary oxalate excretion: Studies using a hyperoxaluric rat model. J Urol 159:2177-2181, 1998
36. HOLMES RP, ASSIMOS DG, LEAF CD, WHALEN JJ: The effects of (L)-2-oxothiazolidine-4-carboxylate on urinary oxalate excretion. J Urol 158:34-37, 1997
37. HOLMES RP, ASSIMOS DG, WILSON DM, MILLINER DS: (L)-2-oxothiazolidine-4- carboxylate in the treatment of primary hyperoxaluria type 1. BJU Int 88:858-862, 2001
38. MERRILL AH JR, HENDERSON JM: Vitamin B6 metabolism by human liver. Ann NY Acad Sci 585:110-117, 1990
39. MEHANSHO H, Buss DD, HAMM MW, HENDERSON LM: Transport and metabolism of pyridoxine in rat liver. Biochim Biophys Acta 631:112-123, 1980
40. WADA H, SNELL EE: The enzymatic oxidation of pyridoxine and pyridoxamine phosphates. J Biol Chem 236:2089-2095, 1961
41. MERRILL AH, HORIIKE K., MCCORMICK DB: Evidence for the regulation of pyridoxal 5-phosphate formation in liver by pyridoxamine (pyridoxine) 5-phosphate oxidase. Biochem Biophys Res Commun 83:984-990, 1978
42. HOLMES RP, ASSIMOS DG: Glyoxylate synthesis, and its modulation and influence on oxalate synthesis. J Urol 160:1617-1624, 1998